Sellas Reports 57% Response Rate in TP53-Mutated AML With SLS009 Combination in Phase 2 Trial
Bitget2026/11/04 14:09- Sellas Life Sciences will present Phase 2 SLS009 combination results in relapsed or refractory acute myeloid leukemia on December 14, 2026.
- SLS009 with azacitidine and venetoclax showed responses in patients whose prior venetoclax-based treatment failed, with encouraging survival versus historical outcomes.
- The combination was well tolerated, with no meaningful added toxicity; benefits included patients with high-risk TP53-mutated or monocytic disease.
- A separate Phase 2 trial in newly diagnosed patients continues enrollment, with initial topline data expected in the fourth quarter of 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
